Please login to the form below

Not currently logged in
Email:
Password:

Roivant

This page shows the latest Roivant news and features for those working in and with pharma, biotech and healthcare.

Metavant/Poxel prep phase 3 for imeglimin in diabetic kidney disease

Metavant/Poxel prep phase 3 for imeglimin in diabetic kidney disease

Roivant Sciences subsidiary Metavant licensed US and European rights to the drug last year for $35m upfront, a $15m equity investment and up to $500m in milestone payments.

Latest news

More from news
Approximately 6 fully matching, plus 9 partially matching documents found.

Latest Intelligence

  • Pharma deals in May 2015 Pharma deals in May 2015

    110. Arena Pharmaceuticals/ Roivant Sciences. Licence agreement. For Nelotanserin a 5-HT2A receptor P2 in behavioural and neuropsychiatric disturbances.

More from intelligence
Approximately 0 fully matching, plus 1 partially matching documents found.

Latest appointments

More from appointments
Approximately 0 fully matching, plus 1 partially matching documents found.

Featured jobs

Subscribe to our email news alerts

PMHub

Add my company
Hanson Zandi

Hanson Zandi is a Creative and Digital Healthcare Agency. We combine 30 years’ experience with the enthusiasm of a start-up...

Latest intelligence

Precision paediatrics: Treating patients with CAR-T
Dr Stuart Adams specialises in using T-cell therapy to treat paediatric patients at Great Ormond Street Hospital. Here, he explains what it was like to develop and deliver a groundbreaking...
What does it mean to be an agile organisation
We spoke with Philip Atkinson to learn how healthcare and pharmaceutical companies can rapidly respond to changes in the market....
Battling breast cancer with precision medicine (Part 2)
Dr Mark Moasser treated breast cancer survivor Laura Holmes-Haddad (interviewed in part one) with an innovative precision medicine, which at the time was yet to be approved. Here he gives...

Infographics